


Schema

Blinded Treatment



Accrual Goal = 800

- 1 Patients must have a history of melanoma of cutaneous, mucosal or unknown primary site. Patients must not have ocular melanoma.
- 2 After four cycles of chemotherapy, the dose of both chemotherapy agents will be reduced by 25% for patients who have not yet had a dose reduction during earlier cycles.
- 3 BAY 43-9006/placebo will be administered twice daily (approximately 12 hours between doses) from day 2 to day 19 of a 21 day cycle. If chemotherapy cannot be administered on schedule, for any reason, patients will remain on BAY 43-9006/placebo until day 2 of the next cycle. For patients who are stable or continue to demonstrate partial or complete response, it is recommended that chemotherapy be discontinued after 10 cycles or sooner in the case of unacceptable toxicity. After the cessation of chemotherapy, BAY 43-9006/placebo will be taken twice daily continuously throughout the cycle.
- 4 Patients are eligible to continue BAY 43-9006/placebo until progression after 10 cycles or sooner in the case of unacceptable toxicity. After the cessation of chemotherapy, BAY 43-9006/placebo will be taken twice daily continuously throughout the cycle.